Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Infection
Interventions: omiganan 1% gel, chlorhexidine 2% solution; Drug
Lead sponsor: Cadence Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Urinary Tract Infections, Prostatitis, Interstitial Cystitis
Interventions: Guidance 4.0 PCR test, Urine Culture; Diagnostic Test
Lead sponsor: Pathnostics; Industry
Eligibility: 18 Years and older
Enrollment: 2,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Pain
Interventions: Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test; Procedure · Behavioral
Lead sponsor: Mount St. Mary's College, Los Angeles, CA; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Wound
Interventions: Conventional bacterial culture, Rapid diagnostic group using mNGS technology; Diagnostic Test · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Sleeve Gastrectomy
Interventions: Alcohol (Ethanol); Drug
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 64 Years
Enrollment: 88 participants
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Overweight and Obesity, Eating Behavior
Interventions: Placebo, Bromocriptine-QR; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions: Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Lupus Erythematosus, Systemic
Interventions: fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 40 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chest Pain, Acute Coronary Syndrome, Angina, Myocardial Infarction
Interventions: Not listed
Lead sponsor: Bayfront Health St Petersburg; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Dade City, Florida • St. Petersburg, Florida

Conditions: Overweight and Obesity
Interventions: Online handouts describing how to follow each diet for 1 week each; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Dose Finding Study
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Austin, Texas

Conditions: Pain Perception, Phlebotomy
Interventions: 4% lidocaine gel application with sham microneedle device, Microneedle-facilitated lidocaine application; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: HIV-1-infection
Interventions: Rapid start of antiretrovirals, Retrospective analysis, Non- RAPID start; Behavioral
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lacerations, Wounds
Interventions: Arm 2: Absorbable sutures, Arm 1: non-absorbable sutures; Other
Lead sponsor: Temple University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: IgM and IgG in Blood
Interventions: Rapid antibody test; Other
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 16 Years to 85 Years
Enrollment: 500 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions: Behavioral Counseling, bupropion-SR; Behavioral · Drug
Lead sponsor: Eva Szigethy; Other
Eligibility: 15 Years to 30 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: CHR-2797; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
Interventions: Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, G-csf, Mesna, CliniMACS, ATG (rabbit), Blinatumomab, TCRα/β+, CD19+, CD45RA-depleted DLI; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV Infections
Interventions: Behavioral counseling, HIV-1 Antibody Test Kit; Other · Device
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 14
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 8 more

Conditions: Acute Promyelocytic Leukemia
Interventions: All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin, Gemtuzumab Ozogamicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgery, Mobility
Interventions: Ambulation; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obesity
Interventions: Eucalaloric feeding, Acute Fasting, Acute Overfeeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis C
Interventions: HCV Screening; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 147,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Denver, Colorado • Baltimore, Maryland • Jackson, Mississippi

Conditions: Diabetic Retinopathy
Interventions: Initiation of treatment of diabetes; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study

The Effects of Pain and the Memory of Pain on Autonomic and Neuromuscular Function

Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification

Alcohol After Bariatric Surgery 2

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Validation of Simple Acute Coronary Syndrome (SACS) Score

The Fasting and Shifted Timing (FAST) of Eating Study

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

Functional Microarray Augmentation of Skin Treatment With Lidocaine

Impact of Rapid ART Initiation on Retention in Care in the Southern US

Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations

Immune Response Following COVID-19 Vaccination

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Real-time Location System Feasibility Study

Thermogenenic Responses to Fasting and Overfeeding in Women

The DETECT HCV Screening Trial

Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia